MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

5.62 -0.18

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.59

Max

5.64

Galvenie mērījumi

By Trading Economics

Ienākumi

42M

-100K

Pārdošana

-15M

196M

EPS

-0.03

Peļņas marža

-0.051

Darbinieki

2,700

EBITDA

-12M

-14M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+54.29% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-827M

489M

Iepriekšējā atvēršanas cena

5.8

Iepriekšējā slēgšanas cena

5.62

Ziņu noskaņojums

By Acuity

81%

19%

354 / 375 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. jūl. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 15:57 UTC

Tirgus saruna

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Tirgus saruna

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Received All Required Authorizations

2025. g. 4. jūl. 15:48 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Agreement Was Announced on Dec. 19

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025. g. 4. jūl. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025. g. 4. jūl. 14:30 UTC

Iegādes, apvienošanās, pārņemšana

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025. g. 4. jūl. 13:53 UTC

Tirgus saruna

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. jūl. 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus -2-

2025. g. 4. jūl. 12:30 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

2025. g. 4. jūl. 12:15 UTC

Tirgus saruna

Targeted Tariffs Would Likely Support Dollar -- Market Talk

2025. g. 4. jūl. 12:13 UTC

Tirgus saruna

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

2025. g. 4. jūl. 12:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

54.29% augšup

Prognoze 12 mēnešiem

Vidējais 8.64 USD  54.29%

Augstākais 18 USD

Zemākais 4 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

14 ratings

4

Pirkt

8

Turēt

2

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

354 / 375 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.